Piper Jaffray analyst William Quirk raised his price target for Fluidigm to $14 from $10 after traveling with management. The analyst is now “incrementally more confident” in Fluidigm’s opportunity to maintain higher mass cytometry growth and opportunistically grow its genomics business. He believes genomics could be the largest source of 2019 upside and that Fluidigm is benefiting from the economies of strong customer relationships such as CareDx. Quirk keeps an Overweight rating on the shares.
https://thefly.com/landingPageNews.php?id=2878271
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.